| Dr Tiffany T Perri, OD | |
|
380 W Main St, Avon, CT 06001-3690 | |
| (860) 409-4565 | |
| Not Available |
| Full Name | Dr Tiffany T Perri |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 12 Years |
| Location | 380 W Main St, Avon, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447506357 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 002863 (Connecticut) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Archdale Eyecare Pc | 0648264408 | 2 |
| Archdale Optometry Corporation | 0345216461 | 4 |
News Archive
A new microfluidics device that uses immobilized antibodies and carbon nanostrings as detection agents can identify slight variations in protein composition, known as protein isoforms, that could indicate the presence of cancer.
Janssen Scientific Affairs, LLC today announced the launch of JanssenMD, a new online scientific resource for U.S. healthcare professionals seeking instant access to current information about Janssen products marketed in the U.S. The web-based application is designed for use on desktops, tablets, and smartphones and can be accessed at www.janssenMD.com.
A team of investigators at Northwestern University has developed a promising nanomaterial-based biomedical device that could be used to deliver chemotherapy drugs locally to sites where cancerous tumors have been surgically removed.
"Pharmaceutical companies, once blasted as uncaring or downright greedy for charging thousands of dollars for a year's worth of AIDS medicines … in poor countries, lately have been slashing prices and licensing their drugs for free or nominal cost to nonprofits or local manufacturers in the developing world," Bloomberg BusinessWeek writes in an analysis piece that examines how this trend, combined with a growing capability among aid agencies to distribute drugs, has the potential to increase access to HIV/AIDS drugs worldwide.
Inhibitex, Inc., announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg, or placebo. The Company plans to present detailed results from this trial during a future scientific meeting.
› Verified 6 days ago
| Provider Name | Archdale Eyecare Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1154457687 PECOS PAC ID: 0648264408 Enrollment ID: O20040413001721 |
News Archive
A new microfluidics device that uses immobilized antibodies and carbon nanostrings as detection agents can identify slight variations in protein composition, known as protein isoforms, that could indicate the presence of cancer.
Janssen Scientific Affairs, LLC today announced the launch of JanssenMD, a new online scientific resource for U.S. healthcare professionals seeking instant access to current information about Janssen products marketed in the U.S. The web-based application is designed for use on desktops, tablets, and smartphones and can be accessed at www.janssenMD.com.
A team of investigators at Northwestern University has developed a promising nanomaterial-based biomedical device that could be used to deliver chemotherapy drugs locally to sites where cancerous tumors have been surgically removed.
"Pharmaceutical companies, once blasted as uncaring or downright greedy for charging thousands of dollars for a year's worth of AIDS medicines … in poor countries, lately have been slashing prices and licensing their drugs for free or nominal cost to nonprofits or local manufacturers in the developing world," Bloomberg BusinessWeek writes in an analysis piece that examines how this trend, combined with a growing capability among aid agencies to distribute drugs, has the potential to increase access to HIV/AIDS drugs worldwide.
Inhibitex, Inc., announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg, or placebo. The Company plans to present detailed results from this trial during a future scientific meeting.
› Verified 6 days ago
| Provider Name | Archdale Optometry Corporation |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1275660565 PECOS PAC ID: 0345216461 Enrollment ID: O20040909000267 |
News Archive
A new microfluidics device that uses immobilized antibodies and carbon nanostrings as detection agents can identify slight variations in protein composition, known as protein isoforms, that could indicate the presence of cancer.
Janssen Scientific Affairs, LLC today announced the launch of JanssenMD, a new online scientific resource for U.S. healthcare professionals seeking instant access to current information about Janssen products marketed in the U.S. The web-based application is designed for use on desktops, tablets, and smartphones and can be accessed at www.janssenMD.com.
A team of investigators at Northwestern University has developed a promising nanomaterial-based biomedical device that could be used to deliver chemotherapy drugs locally to sites where cancerous tumors have been surgically removed.
"Pharmaceutical companies, once blasted as uncaring or downright greedy for charging thousands of dollars for a year's worth of AIDS medicines … in poor countries, lately have been slashing prices and licensing their drugs for free or nominal cost to nonprofits or local manufacturers in the developing world," Bloomberg BusinessWeek writes in an analysis piece that examines how this trend, combined with a growing capability among aid agencies to distribute drugs, has the potential to increase access to HIV/AIDS drugs worldwide.
Inhibitex, Inc., announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg, or placebo. The Company plans to present detailed results from this trial during a future scientific meeting.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tiffany T Perri, OD 7095 Lexington Dr, Colorado Springs, CO 80918-6329 Ph: (860) 409-4565 | Dr Tiffany T Perri, OD 380 W Main St, Avon, CT 06001-3690 Ph: (860) 409-4565 |
News Archive
A new microfluidics device that uses immobilized antibodies and carbon nanostrings as detection agents can identify slight variations in protein composition, known as protein isoforms, that could indicate the presence of cancer.
Janssen Scientific Affairs, LLC today announced the launch of JanssenMD, a new online scientific resource for U.S. healthcare professionals seeking instant access to current information about Janssen products marketed in the U.S. The web-based application is designed for use on desktops, tablets, and smartphones and can be accessed at www.janssenMD.com.
A team of investigators at Northwestern University has developed a promising nanomaterial-based biomedical device that could be used to deliver chemotherapy drugs locally to sites where cancerous tumors have been surgically removed.
"Pharmaceutical companies, once blasted as uncaring or downright greedy for charging thousands of dollars for a year's worth of AIDS medicines … in poor countries, lately have been slashing prices and licensing their drugs for free or nominal cost to nonprofits or local manufacturers in the developing world," Bloomberg BusinessWeek writes in an analysis piece that examines how this trend, combined with a growing capability among aid agencies to distribute drugs, has the potential to increase access to HIV/AIDS drugs worldwide.
Inhibitex, Inc., announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg, or placebo. The Company plans to present detailed results from this trial during a future scientific meeting.
› Verified 6 days ago
Oculus, Llc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 380 W Main St, Lenscrafters, Avon, CT 06001 Phone: 860-409-4565 | |
Dr. Pari Shah, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 49 W Main St, Avon, CT 06001 Phone: 860-676-2376 | |
Dr. Harneet Dhillon Mcdermott, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 43 W Main St, Avon, CT 06001 Phone: 860-676-2376 | |
Dr. Michael James Shiembob, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 315 West Main Street, Avon, CT 06001 Phone: 860-678-3937 Fax: 860-678-7217 | |
Dr. Beth A Salonia, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 380 W Main St, Avon, CT 06001 Phone: 860-409-4565 | |
Dr. Pamela Carol Malchoff, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 18 W Avon Rd, Avon, CT 06001 Phone: 860-675-3937 Fax: 860-673-2555 | |
Dr. Daniel Thomas Fitzpatrick, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 40 Avon Meadow Lane, Avon, CT 06001 Phone: 860-677-6444 Fax: 860-677-4836 |